In this comment letter PCMA opposes AB 315. This bill would require PBMs to be regulated by the California Board of Pharmacy, and would grant broad rulemaking authority to the board. The bill would also require the public disclosure of competitively sensitive business information. We are concerned that both policies would undercut competition in the drug marketplace and raise prescription drug prices for consumers.